Table 4.
Cognitive outcomes in Thai children, at age 1 and, 2 years, by group.
| n | 1 year | Mean difference (95% CI) | P | n | 2 year | Mean difference (95% CI) | Pa | |
|---|---|---|---|---|---|---|---|---|
| BSID-III, Cognitiveb | ||||||||
| Iodine | 85 | 42 (40–45) | 1.1 (0.01 to 2.3) | 0.08 | 108 | 62 (59–64) | −0.2 (−1.4 to 0.9) | 0.52 |
| Placebo | 92 | 42 (40–43) | 110 | 62 (59–65) | ||||
| BSID-III, Language receptive | ||||||||
| Iodine | 85 | 12 (11–13) | 0.4 (−0.04 to 0.8) | 0.18 | 107 | 26 (24–29) | 0.5 (−0.7 to 1.7) | 0.60 |
| Placebo | 90 | 12 (11–12) | 108 | 25 (23–28) | ||||
| BSID-III, Language expressive | ||||||||
| Iodine | 85 | 13 (11–14) | −0.05 (−0.8 to 0.7) | 0.65 | 104 | 29 (26–31) | 0.9 (−0.4 to 2.3) | 0.38 |
| Placebo | 90 | 13 (12–15) | 104 | 29 (26–31) | ||||
| BSID-III, Language combined | ||||||||
| Iodine | 85 | 25 (23–28) | 0.3 (−0.6 to 1.3) | 0.79 | 104 | 55 (50–59) | 1.5 (−0.8 to 3.8) | 0.40 |
| Placebo | 90 | 25 (23–27) | 104 | 54 (49–58) | ||||
| BSID-III, Fine motor | ||||||||
| Iodine | 85 | 29 (28–30) | 0.3 (−0.3 to 0.9) | 0.41 | 106 | 37 (36–39) | −0.3 (−0.9 to 0.4) | 0.37 |
| Placebo | 90 | 29 (27–30) | 108 | 38 (36–39) | ||||
| BSID-III, Gross motor | ||||||||
| Iodine | 84 | 41 (38–44) | −0.2 (−1.5 to 1.0) | 0.39 | 104 | 54 (52–55) | −0.8 (−1.6 to 0.03) | 0.07 |
| Placebo | 90 | 41 (38–44) | 107 | 54 (52–56) | ||||
| BSID-III, Motor combined | ||||||||
| Iodine | 84 | 70 (66–73) | 0.1 (−1.4 to 1.6) | 0.76 | 103 | 91 (89–93) | −1.1 (−2.2 to 0.03) | 0.05 |
| Placebo | 90 | 70 (67–73) | 107 | 92 (90–94) | ||||
a
Data were analyzed using linear mixed effect models testing treatment effect while controlling for household average monthly income, maternal education, child's birthweight, child's age and child's sex.
b
Median (IQR) all such values.
BSID-III, Bayley Scales of Infant Development Third Edition.